Augustin, M <br/><br/>
Continued treatment with secukinumab is associated with high retention or regain of response.  [electronic resource] 

 -  The British journal of dermatology  01 2020 
 - 67-75 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1365-2133 
<br/><br/><label>Standard No.: </label>10.1111/bjd.17991  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal, Humanized<br/>Etanercept<br/>Humans<br/>Psoriasis--drug therapy<br/>Randomized Controlled Trials as Topic<br/>Severity of Illness Index<br/>Treatment Outcome<br/>Ustekinumab